AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38197815 — intervention group
Group type: EXPERIMENTAL
Intervention: Repotrectinib (160 mg daily for 14 days, then 160 mg twice daily)
Number of subjects: 71
Study 38197817 — intervention group
Group type: EXPERIMENTAL
Intervention: 500-mg daily dose of calcium supplementation
Number of subjects: 11000
Study 38197817 — intervention group
Group type: COMPARATOR
Intervention: 1500-mg daily dose of calcium supplementation
Number of subjects: 11000
Study 38197816 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoramidis hydrochloride at a dose of 800 mg twice daily
Number of subjects: 632
Study 38197816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 632
Study 38197863 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonal hematopoiesis of indeterminate potential (CHIP) identified among PWH
Number of subjects: 4486
Study 38197863 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 4486
Study 38197863 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 4486
Study 38197863 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographic origin (outside North America)
Number of subjects: 4486
Study 38197863 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic/Latino ethnicity
Number of subjects: 4486
Study 38197863 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 nadir <50 cells/mm3
Number of subjects: 4486
Study 38197863 — intervention group
Group type: EXPERIMENTAL
Intervention: Short duration of antiretroviral therapy (ART)
Number of subjects: 4486
Study 38197938 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax and azacitidine (Ven/Aza) maintenance therapy: Aza 36 mg/m2 intravenously on days 1 to 5, and Ven 400 mg by mouth on days 1 to 14 (42-day cycles × 8, or 28-day cycles × 12)
Number of subjects: 27
Study 38197938 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 27
Study 38197938 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax and azacitidine (Ven/Aza) maintenance therapy
Number of subjects: 27
Study 38197947 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality sessions (6 sessions with Nintendo Switch)
Number of subjects: 58
Study 38197947 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation sessions only
Number of subjects: 58
Study 38198010 — intervention group
Group type: EXPERIMENTAL
Intervention: HRS-2261 (25, 100, 200, 400, 800, and 1200 mg)
Number of subjects: 92
Study 38198010 — intervention group
Group type: EXPERIMENTAL
Intervention: HRS-2261 (50, 200, and 400 mg)
Number of subjects: 92
Study 38198010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 38198053 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive intravitreal aflibercept (IVT-AFL) treatment regimens (fixed dosing or treat-and-extend)
Number of subjects: 1466
Study 38198106 — intervention group
Group type: EXPERIMENTAL
Intervention: Carglumic acid treatment for at least 1 year
Number of subjects: 10
Study 38198141 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-stay unit (SSU) care
Number of subjects: 194
Study 38198141 — intervention group
Group type: COMPARATOR
Intervention: Hospitalization
Number of subjects: 194
Study 38198456 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA-assisted therapy
Number of subjects: 90
Study 38198456 — intervention group
Group type: COMPARATOR
Intervention: Therapy with placebo
Number of subjects: 90
Study 38198792 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated Glucose Disposal Rate (eGDR)
Number of subjects: 287
Study 38198792 — intervention group
Group type: COMPARATOR
Intervention: Lowest eGDR tertile (highest level of IR)
Number of subjects: 287
Study 38198792 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic-euglycemic clamp (HEC)
Number of subjects: 287
Study 38199147 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab + cyclophosphamide and vinblastine (arm A)
Number of subjects: 16
Study 38199147 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab + capecitabine (arm B)
Number of subjects: 16
Study 38199147 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab + cyclophosphamide, vinblastine and capecitabine (arm C)
Number of subjects: 16
Study 38199147 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 16
Study 38199288 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 μg
Number of subjects: 771
Study 38199288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 771
Study 38199593 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 521
Study 38199593 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction
Number of subjects: 521
Study 38199593 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy
Number of subjects: 521
Study 38199593 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 521
Study 38199617 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral challenge with one of two strains of non-typhoidal
Number of subjects: 40
Study 38199617 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study 38199626 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerns about stopping score (measured using the rPATD questionnaire)
Number of subjects: 298
Study 38199626 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement with deprescribing
Number of subjects: 298
Study 38199626 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of prescribing recommendations from the OPTICA medication review
Number of subjects: 298
Study 38199626 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in the number of long-term medications
Number of subjects: 298
Study 38199626 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in medication appropriateness (Medication Appropriateness Index)
Number of subjects: 298
Study 38199628 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle Strengthening Training (MST) for 12 weeks
Number of subjects: 90
Study 38199628 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural Graded Activity (BGA) for 12 weeks
Number of subjects: 90
Study 38199628 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control group)
Number of subjects: 90
Study 38199634 — intervention group
Group type: EXPERIMENTAL
Intervention: HOW R U? weekly volunteer-peer support telephone intervention
Number of subjects: 141
Study 38199634 — intervention group
Group type: EXPERIMENTAL
Intervention: HOW R U? delivered using a video-conferencing solution
Number of subjects: 141
Study 38199634 — intervention group
Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 141
Study 38199635 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended pancreatic neck transection
Number of subjects: 154
Study 38199635 — intervention group
Group type: COMPARATOR
Intervention: Conventional pancreatic neck transection
Number of subjects: 154
Study 38199637 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAN-RAY risk assessment strategy
Number of subjects: 750
Study 38199637 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report questionnaires
Number of subjects: 750
Study 38199637 — intervention group
Group type: EXPERIMENTAL
Intervention: Semistructured interviews
Number of subjects: 750
Study 38199641 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple assessment modalities for physical function
Number of subjects: 200
Study 38199641 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable sensor and patient-centred health data aggregating platform
Number of subjects: 200
Study 38199641 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal physical function assessments
Number of subjects: 200
Study 38199641 — intervention group
Group type: EXPERIMENTAL
Intervention: Feasibility of multimodal physical function data collection
Number of subjects: 200
Study 38199751 — intervention group
Group type: EXPERIMENTAL
Intervention: Target lesion revascularization (TLR) after percutaneous coronary intervention (PCI) with drug-eluting stents (DES)
Number of subjects: 1397
Study 38199751 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of TLR
Number of subjects: 1397
Study 38199789 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (single round of ovarian stimulation with hCG triggering)
Number of subjects: 46
Study 38199789 — intervention group
Group type: COMPARATOR
Intervention: Group B (two uninterrupted rounds of ovarian stimulation with GnRH agonist triggering)
Number of subjects: 46
Study 38199789 — intervention group
Group type: COMPARATOR
Intervention: Comparison of cumulative outcomes between Group A and Group B
Number of subjects: 46
Study 38199870 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3
Number of subjects: 2157
Study 38199870 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D
Number of subjects: 2157
Study 38199870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2157
Study 38200171 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedling radiofrequency (RF) treatment continued monthly over 6 months after 2 months of conventional therapy.
Number of subjects: 15
Study 38200171 — intervention group
Group type: COMPARATOR
Intervention: Untreated side (control group).
Number of subjects: 15
Study 38200233 — intervention group
Group type: EXPERIMENTAL
Intervention: DFMO (up to 9000 mg/m) with celecoxib, cyclophosphamide, and topotecan
Number of subjects: 24
Study 38200320 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept 0.4 mg/eye
Number of subjects: 113
Study 38200320 — intervention group
Group type: COMPARATOR
Intervention: Laser photocoagulation
Number of subjects: 113
Study 38200325 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 0.5-1 mcg/kg intravenously
Number of subjects: 324
Study 38200325 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline solution intravenously
Number of subjects: 324
Study 38200410 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoimmunotherapy (Arm A)
Number of subjects: 0
Study 38200410 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy followed by monoimmunotherapy (Arm B)
Number of subjects: 0
Study 38200410 — intervention group
Group type: EXPERIMENTAL
Intervention: XELIRI six cycle regime (Arm C)
Number of subjects: 0
Study 38200410 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX nine cycle regime (Arm D)
Number of subjects: 0
Study 38200410 — intervention group
Group type: EXPERIMENTAL
Intervention: Watch and wait (W&W) strategy
Number of subjects: 0
Study 38200410 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mesorectal excision (TME)
Number of subjects: 0
Study 38200419 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral therapy
Number of subjects: 456
Study 38200419 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained virologic response (SVR)
Number of subjects: 456
Study 38200419 — intervention group
Group type: EXPERIMENTAL
Intervention: Sociodemographic factors (gender, age, income, genotype)
Number of subjects: 456
Study 38200486 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-choice based concentrated group rehabilitation
Number of subjects: 241
Study 38200581 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg daily)
Number of subjects: 63
Study 38200621 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated pulse-wave velocity (ePWV)
Number of subjects: 15773
Study 38200621 — intervention group
Group type: EXPERIMENTAL
Intervention: Each m·s-1 increase in ePWV
Number of subjects: 15773
Study 38200621 — intervention group
Group type: EXPERIMENTAL
Intervention: ePWV
Number of subjects: 15773
Study 38202070 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 79
Study 38202070 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 79
Study 38203214 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent regorafenib
Number of subjects: 0
Study 38203593 — intervention group
Group type: EXPERIMENTAL
Intervention: AAT treatment
Number of subjects: 53
Study 38204184 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Training (HIT)
Number of subjects: 0
Study 38204184 — intervention group
Group type: COMPARATOR
Intervention: Conventional Training
Number of subjects: 0
Study 38204364 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tramadol/dexketoprofen (TRAM/DKP)
Number of subjects: 323
Study 38204364 — intervention group
Group type: COMPARATOR
Intervention: Intravenous paracetamol + tramadol (PARA+TRAM)
Number of subjects: 323
Study 38204489 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib plus atezolizumab
Number of subjects: 61
Study 38204488 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor-derived anti-CD19 CAR T cells (GC007g)
Number of subjects: 12
Study 38204600 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid-filled wire (Wirecath)
Number of subjects: 45
Study 38204600 — intervention group
Group type: COMPARATOR
Intervention: Conventional pressure wire (PressureWire X)
Number of subjects: 45
Study 38204726 — intervention group
Group type: EXPERIMENTAL
Intervention: mGEARS score
Number of subjects: 0
Study 38204726 — intervention group
Group type: EXPERIMENTAL
Intervention: TBS
Number of subjects: 0
Study 38204726 — intervention group
Group type: EXPERIMENTAL
Intervention: mGEARS and TBS
Number of subjects: 0
Study 38204726 — intervention group
Group type: EXPERIMENTAL
Intervention: mGEARS
Number of subjects: 0
Study 38204866 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit training combining strength (50%-80% 1RM) and endurance (50%-75% HRR) exercise, 33 minutes, three times per week for 12 weeks
Number of subjects: 27
Study 38204866 — intervention group
Group type: COMPARATOR
Intervention: Control non-training group (NT)
Number of subjects: 27
Study 38204945 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular-phase stimulation (FPS)
Number of subjects: 41
Study 38204945 — intervention group
Group type: COMPARATOR
Intervention: Luteal-phase stimulation (LPS)
Number of subjects: 41
Study 38204957 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular phase length (FPL) quintiles (q1: ≤11 days, q2: 12 days, q3: 13 days, q4: 14-15 days, q5: ≥16 days)
Number of subjects: 869
Study 38204957 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate or letrozole
Number of subjects: 869
Study 38204957 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropins
Number of subjects: 869
Study 38204957 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups combined
Number of subjects: 869
Study 38205016 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer-associated thrombosis management over time
Number of subjects: 17271
Study 38205016 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic VTE recurrences
Number of subjects: 17271
Study 38205016 — intervention group
Group type: EXPERIMENTAL
Intervention: Major bleeding
Number of subjects: 17271
Study 38205016 — intervention group
Group type: EXPERIMENTAL
Intervention: Death within 30 days after incident VTE
Number of subjects: 17271
Study 38205035 — intervention group
Group type: EXPERIMENTAL
Intervention: MTC online program during the 8-week period
Number of subjects: 200
Study 38205035 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group receiving the MTC program after an 8-week wait
Number of subjects: 200
Study 38205442 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal delivery of a bicistronic AAV9 vector expressing β-hexosaminidase A
Number of subjects: 1
Study 38205442 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1
Study 38205507 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus cyclophosphamide and dexamethasone
Number of subjects: 0
Study 38205654 — intervention group
Group type: EXPERIMENTAL
Intervention: High noncalcified plaque (NCP) volume
Number of subjects: 454
Study 38205654 — intervention group
Group type: COMPARATOR
Intervention: Low noncalcified plaque (NCP) volume
Number of subjects: 454
Study 38205654 — intervention group
Group type: EXPERIMENTAL
Intervention: High NCP volume
Number of subjects: 454
Study 38205656 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg subcutaneously every 14 days in addition to high-intensity statin therapy
Number of subjects: 104
Study 38205679 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of allogeneic adipose-derived mesenchymal stem cells (ADSCs) GXCPC1
Number of subjects: 11
Study 38205822 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam with flumazenil
Number of subjects: 0
Study 38205822 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 0
Study 38205865 — intervention group
Group type: EXPERIMENTAL
Intervention: Low educational level
Number of subjects: 2295
Study 38205865 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium educational level
Number of subjects: 2295
Study 38205865 — intervention group
Group type: COMPARATOR
Intervention: High educational level
Number of subjects: 2295
Study 38205865 — intervention group
Group type: EXPERIMENTAL
Intervention: All-cause death
Number of subjects: 2295
Study 38205865 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic stroke (IS)
Number of subjects: 2295
Study 38205865 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracerebral hemorrhage (ICH)
Number of subjects: 2295
Study 38206145 — intervention group
Group type: EXPERIMENTAL
Intervention: Clascoterone cream 1%
Number of subjects: 1421
Study 38206151 — intervention group
Group type: EXPERIMENTAL
Intervention: PLLA-SCA injections (150 mg; 8 mL reconstitution in sterile water for injection) + 1 mL lidocaine hydrochloride (2%)
Number of subjects: 0
Study 38206151 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 0
Study 38206151 — intervention group
Group type: EXPERIMENTAL
Intervention: PLLA-SCA injections
Number of subjects: 0
Study 38206187 — intervention group
Group type: EXPERIMENTAL
Intervention: Doravirine (biological cutoff 3.0)
Number of subjects: 2705
Study 38206187 — intervention group
Group type: EXPERIMENTAL
Intervention: V106I
Number of subjects: 2705
Study 38206187 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtype F1
Number of subjects: 2705
Study 38206455 — intervention group
Group type: EXPERIMENTAL
Intervention: Current moderate exacerbation
Number of subjects: 0
Study 38206455 — intervention group
Group type: EXPERIMENTAL
Intervention: Current severe exacerbation
Number of subjects: 0
Study 38206455 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous moderate exacerbation
Number of subjects: 0
Study 38206455 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous severe exacerbation
Number of subjects: 0
Study 38206518 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosimilars (TNF inhibitors) - adalimumab (ADA), etanercept (ETA), infliximab (IFX)
Number of subjects: 47
Study 38206518 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosimilars (TNF inhibitors)
Number of subjects: 47
Study 38206544 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord mesenchymal stem cells transplantation (UMSCT)
Number of subjects: 41
Study 38206548 — intervention group
Group type: EXPERIMENTAL
Intervention: Lock to Live (L2L) decision aid
Number of subjects: 21131
Study 38206548 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 21131
Study 38206614 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cohort (4 Gy × 10 fractions + 25 Gy SABR boost, 5 Gy × 5 fractions)
Number of subjects: 28
Study 38206614 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-dose cohort (4 Gy × 10 fractions + 30 Gy SABR boost, 6 Gy × 5 fractions)
Number of subjects: 28
Study 38206614 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cohort (4 Gy × 10 fractions + 35 Gy SABR boost, 7 Gy × 5 fractions)
Number of subjects: 28
Study 38206628 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Lateral Approach (DLA)
Number of subjects: 843
Study 38206628 — intervention group
Group type: COMPARATOR
Intervention: Posterolateral Approach (PLA)
Number of subjects: 843
Study 38206631 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine 15 mg for 2 weeks followed by 30 mg until week 8
Number of subjects: 86
Study 38206631 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 86
Study 38206631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 38206635 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA ≤200 U
Number of subjects: 730
Study 38206635 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA 201-400 U
Number of subjects: 730
Study 38206635 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA 401-600 U
Number of subjects: 730
Study 38206635 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA 601-800 U
Number of subjects: 730
Study 38206635 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA ≥801 U
Number of subjects: 730
Study 38206635 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Number of subjects: 730
Study 38206678 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisaborole
Number of subjects: 0
Study 38206678 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38206766 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-4 treatment
Number of subjects: 15
Study 38206766 — intervention group
Group type: EXPERIMENTAL
Intervention: EOS conditioned media
Number of subjects: 15
Study 38206766 — intervention group
Group type: COMPARATOR
Intervention: Obesity (n = 15)
Number of subjects: 15
Study 38206766 — intervention group
Group type: COMPARATOR
Intervention: Lean subjects (n = 15)
Number of subjects: 15
Study 38206830 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel 120 mg plus Temozolomide (TMZ)
Number of subjects: 57
Study 38206830 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel 120 mg maintenance
Number of subjects: 57
Study 38206830 — intervention group
Group type: COMPARATOR
Intervention: Observation only (Control)
Number of subjects: 57
Study 38206830 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (LAN plus TMZ)
Number of subjects: 57
Study 38206849 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal training program
Number of subjects: 44
Study 38206849 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based program
Number of subjects: 44